Email:   |  Call: 6109452007


Anti-BRaf(V600E) Mouse Monoclonal Antibody


Cat.#:  26039

   Size:   100 μl

In Stock

          Product Description          
Cat. #:   26039
Gene Symbol:  BRaf
Description:   Anti-BRaf(V600E) Mouse Monoclonal Antibody
Background:   B-Raf is a member of the Raf family of Ser/Thr protein kinases. It functions downstream of Ras to regulate the MAP kinase signaling pathway. Mutations in the BRAF gene cause diseases. Inherited mutations in BRAF cause cardiofaciocutaneous syndrome. Acquired mutations in BRAF have been found in cancers
Immunogen:   A synthetic peptide from the internal region of BRaf(V600E), human origin.
Applications:   ELISA, WB, IHC, IP
Recommended Dilutions:    ELISA: 1:100-1:5000 WB: 1:100-1:2000 IHC: 1:100-1:1000
Concentration:   1 mg/ml
Host Species:   Mouse
Format:   Liquid
Clonality:   Monoclonal
Isotype:   IgG2b
Purity:   Purified from ascites
Storage buffer:
Preservative:  No
Constituents:  PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 50% glycerol
Species Reactivity:  Recognizes B-Raf(V600E), but not wild type B-Raf proteins from vertebrates.
Storage Conditions:  Store at -20°C. Avoid repeated freezing and thawing
Western blot:  

Western blot analysis of recombinant B-raf proteins with anti-BRaf(V600E) antibody. Purified His – tagged B-Raf( V600E ) ?amino acids 513-693)(lane1) ? corresponding wild type protein(lane 2), His – tagged B-Raf( V600D ) (lane 3) , His – tagged B-Raf( V600A ) (lane 4) , His – tagged B-Raf( V600G ) (lane 5) , His – tagged B-Raf( V600K ) (lane 6), His – tagged B-Raf( V600R ) (lane 7), and His – tagged B-Raf( V600M ) (lane 8) were blotted with anti-B-Raf(V600E) monoclonal antibody (Cat # 26039) . Immunofluorescence:   Immunofluorescence of cell expressing BRaf protein with anti-BRaf(V600E) antibody . HEK293T cells were transfected with pCDNA3-GFP- B-Raf( V600E )plasmid,pCDNA3-GFP- B-Raf( WT )plasmid, pCDNA3-GFP- B-Raf( V600K )plasmid,pCDNA3-GFP- B-Raf( V600R )plasmid, pCDNA3-GFP- B-Raf( V600A )plasmid,pCDNA3-GFP- B-Raf( V600D ) plasmid, pCDNA3-GFP-B-Raf(V600M)plasmid, or pCDNA3-GFP-B-Raf(V600G)plasmid, then fixed and stained with anti-B-Raf(V600E) monoclonal antibody (Cat. # 26039). Immunohistochemistry:    B-Raf(V600E) monoclonal antibody (Cat. # 26039). Tissue samples were fixed with formaldehyde and blocked with 1% serum for 15 min at 37 °C. Antigen retrieval was by heat mediation in citrate buffer (pH6). Samples were then incubated with primary antibody (1:100) overnight at 4°C. A HRP-conjugated Goat anti-mouse IgG (dilution 1:50) was used as secondary antibody. 310936477332.png   Immunohistochemical analysis of paraffin-embedded Thyroid Carcinoma tissue -with anti-BRaf (V600E) monoclonal antibody (Cat. # 26039). Tissue samples were fixed with paraffin. Samples were then incubated with primary antibody (1:100) overnight at 4°C. An HRP-conjugated Goat anti-mouse IgG (dilution 1:50) was used as the secondary antibody. Allele-specific PCR validated to be Negative for BRAF V600E. 图片.png Immunohistochemical analysis of paraffin-embedded Thyroid Carcinoma tissue -with anti BRaf(V600E) monoclonal antibody (Cat. # 26039). Tissue samples were fixed with paraffin. Samples were then incubated with primary antibody (1:100) overnight at 4°C.A HRP-conjugated Goat anti-mouse IgG (dilution 1:50) was used as secondary antibody.Allele specific PCR validated to be Negative for BRAF V600E.  
          Related Products          
01. Membrane Anchorage-Induced (MAGIC) Knockdown of Non-synonymous Point Mutations
Chembiochem. 2022  PMID: 35352864
02. Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation
J Hematol Oncol. 2022  PMID:  35978321
03. Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling
Cancer Discov. 2021  PMID:  33568355
04. Prognostic value of TERT promoter mutations in conjunctival melanomas in addition to clinicopathological features
Br J Ophthalmol. 2021  PMID:  33127831
05. Inhibitors of BRAF dimers using an allosteric site
Nat Commun. 2020  PMID:  32873792
06. ZNF703 is Overexpressed in Papillary Thyroid Carcinoma Tissues and Mediates K1 Cell Proliferation
Pathol Oncol Res. 2020  PMID:  30361900
07. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAFV600E Mutant Thyroid Cancer Cells by Constraining DNA Double-strand Break Repair
Clin Cancer Res. 2019  PMID:  31097454
08. PES1 promotes the occurrence and development of papillary thyroid cancer by upregulating the ERα/ERβ protein ratio
Sci Rep. 2019  PMID:  30705367
09. Screening of monomers from traditional Chinese medicine for specifically inhibiting BRAFV600E CT26 cells
中国药理学通报. 2019  PMID: 
10. Activation of Grm1 expression by mutated BRaf (V600E) in vitro and in vivo
Oncotarget. 2018  PMID:  29464040
11. Clinical, Histologic, and Immunophenotypic Features of Serrated Polyps in Patients With Inflammatory Bowel Disease
Gastroenterology Res. 2018  PMID:  30344807
12. Antibody-mediated depletion of protein variant expression in living cells (Protein interference)
BioRXiv 2017  PMID:  0
13. Nuclear morphometric findings in undetermined cytology: A possible clue for prediction of BRAF mutation in papillary thyroid carcinomas
Endocr Res. 2017  PMID: 27911099
14. Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy
Oncotarget. 2017  PMID: 28938534
15. Concomitant high expression of BRAFV600E, P-cadherin and cadherin 6 is associated with High TNM stage and lymph node metastasis in conventional papillary thyroid carcinoma
Clin Endocrinol (Oxf). 2016  PMID: 26285159
16. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature
J Surg Res. 2016  PMID: 27363650
17. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922
Oncotarget. 2016  PMID: 27391062
18. A Novel Approach for the Detection and Genetic Analysis of Live Melanoma Circulating Tumor Cells
PLoS One. 2015  PMID: 25807549
19. Application of immunohistochemistry in thyroid pathology
Arch Pathol Lab Med. 2015  PMID: 25549145
20. BRAF V600E mutation-specific antibody: A review
Seminars in Diagnostic Pathology. 2015  PMID: 25744437
21. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma
human pathology. 2015  PMID: 25442222
22. Are all RAS mutations the same? Coexisting KRAS and NRAS mutations in a caecal adenocarcinoma and contiguous tubulovillous adenoma
J Clin Pathol. 2015   PMID: 25926041
23. BRAF V600E immunohistochemistry is reliable in primary and metastatic colorectal carcinoma regardless of treatment status and shows high intratumoral homogeneity
Am J Surg Pathol. 2014  PMID: 24921639
24. Identification of recurrent SMO and BRAF mutations in ameloblastomas
Nat Genet. 2014  PMID: 24859340
25. Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients
Tumor Biology. 2014  PMID: 24563339
26. Potential Utility of Mutant Oncogene-Specific Antibodies in Melanoma
Am J Dermatopathol. 2014   PMID: 23823028
27. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas
human pathology. 2013  PMID: 24071017
28. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma
Mod Pathol. 2013  PMID:  23041829